The Fox Chase Chemical Diversity Center, Inc. (FCCDC)
The Fox Chase Chemical Diversity Center Announces it is Licensing to Basilea Pharmaceutica, Ltd. a Broad Spectrum Anti-Fungal Platform Technology
Doylestown, PA. April 27, 2022 - FCCDC is pleased to announce that FCCDC is licensing to Basilea Pharmaceutica, Ltd. a broad spectrum anti-fungal platform technology exemplified by preclinical development candidate FC-12406. See the FCCDC press release and the Basilea press release. This program was funded by a >$4M contract from the U.S. Department of Defense (Rick Scott, PI).